Association Between MScanFit Motor Unit Number Estimation and Clinical Function and Response to Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy

被引:0
|
作者
Hansen, Peter N. [1 ]
Mohammed, Abdullahi A. [1 ]
Markvardsen, Lars K. [2 ]
Andersen, Henning [2 ]
Tankisi, Hatice [3 ]
Sindrup, Soren H. [1 ,4 ]
Kroigard, Thomas [1 ,4 ]
机构
[1] Univ Southern Denmark, Odense Univ Hosp, Neurol Res Unit, Odense, Denmark
[2] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Neurophysiol, Aarhus, Denmark
[4] Odense Univ Hosp, Odense Patient Data Explorat Network OPEN, Odense, Denmark
关键词
axonal loss; chronic inflammatory demyelinating polyneuropathy; immunoglobulin; motor unit number estimation; MScanFit; INTRAVENOUS IMMUNOGLOBULIN; DOUBLE-BLIND; AXONAL LOSS; POLYRADICULONEUROPATHY; SCALE; SENSITIVITY; DISABILITY; NEUROPATHY; SCLEROSIS; DIAGNOSIS;
D O I
10.1111/jns.70001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and AimsLoss of motor units in chronic inflammatory demyelinating polyneuropathy is difficult to assess by conventional nerve conduction due to collateral innervation. We aimed to assess the association between a motor unit number estimate (MUNE) derived from the compound muscle action potential (CMAP) scan using MScanFit and hand function and the clinical response to intravenous immunoglobulin (IVIG). MethodsForty-nine CIDP patients and 52 control subjects were included. CMAP scan recordings were obtained from the right abductor pollicis brevis muscle. The primary outcome was the correlation between MUNE and the duration of the nine-hole-peg test (9-HPT) at baseline and the change in the duration of the 9-HPT following treatment with IVIG. Secondary outcomes were grip strength, 10-m-walk test, six-spot-step test, medical research council sum score, inflammatory neuropathy cause and treatment sensory sum score, overall neuropathy limitations scale, and the Rasch-built overall disability scale (R-ODS). ResultsMScanFit analysis suggested both loss of motor units (reduced MUNE (p = 0.022) and N50 (p < 0.0001)) and collateral reinnervation (increased median amplitude (p < 0.0001) and size of the largest unit (p < 0.0001)) in CIDP patients compared to controls. In CIDP patients, there was a statistically significant correlation between MUNE and the duration of the 9-HPT (Spearman's r = -0.342; p = 0.016). Further, patients with a low MUNE had the largest reduction in the duration of the 9-HPT following IVIG treatment (r = -0.577; p = 0.043). MUNE also correlated significantly with R-ODS (r = -0.722; p = 0.007). InterpretationMScanFit MUNE could be a useful method for assessing motor axonal loss in CIDP, which correlates with the clinical function and treatment response.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cost of illness, cost of immunoglobulin therapy and their determinants in chronic inflammatory demyelinating polyneuropathy
    Rajabally, Yusuf A.
    MUSCLE & NERVE, 2019, 59 (03) : E22 - E22
  • [22] Immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: Intravenous versus subcutaneous administration
    Viola, Divina Valeria
    Govoni, Alessandra
    Schirinzi, Erika
    Merico, Elena
    Siciliano, Gabriele
    Calabrese, Rosanna
    Chico, Lucia
    Bacci, Andrea
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [23] Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein
    Stamboulis, E
    Theodorou, V
    Kilidireas, K
    Apostolou, T
    EUROPEAN NEUROLOGY, 2004, 51 (01) : 51 - 51
  • [24] ITALIAN REGISTER TO THERAPY RESPONSE IN PATIENTS WITH CHRONIC DEMYELINATING INFLAMMATORY POLYNEUROPATHY
    Cocito, D.
    Paolasso, I
    Antonini, G.
    Benedetti, L.
    Briani, C.
    Comi, C.
    Fazio, R.
    Jann, S.
    Mata, S.
    Mazzeo, A.
    Sabatelli, M.
    Nobile-Orazio, E.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2009, 14 : 9 - 9
  • [25] ITALIAN REGISTER OF THERAPY RESPONSE IN PATIENTS WITH CHRONIC DEMYELINATING INFLAMMATORY POLYNEUROPATHY
    Cocito, D.
    Paolasso, I
    Antonini, G.
    Benedetti, L.
    Briani, C.
    Comi, C.
    Fazio, R.
    Jann, S.
    Mata, S.
    Mazzeo, A.
    Sabatelli, M.
    Nobile-Orazio, E.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2009, 14 : 35 - 35
  • [26] INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY IN PEDIATRIC PATIENTS: AN OBSERVATIONAL STUDY
    Watson, D. J.
    Martinez, C.
    Wallenhorst, C.
    Hubsch, A.
    Shebl, A.
    Simon, T. L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 409 - 409
  • [27] CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY - CONDUCTION FAILURE BEFORE AND DURING IMMUNOGLOBULIN OR PLASMA THERAPY
    VANDERMECHE, FGA
    VERMEULEN, M
    BUSCH, HFM
    BRAIN, 1989, 112 : 1563 - 1571
  • [28] MAINTENANCE THERAPY WITH SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A LONGTERM FOLLOWUP
    Harvey, Brittany
    Tucker, Natalie
    Hart, Adam
    Katzin, Lara
    Farias, Jerrica
    Jones, Nichole
    Dang, Samuel
    Gooch, Clifton
    Vu, Tuan
    MUSCLE & NERVE, 2016, 54 (03) : 575 - 575
  • [29] INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A SYSTEMATIC LITERATURE REVIEW
    Anderson-Smits, Colin
    Mitchell, Sarah
    Hawe, Emma
    Hartley, Louise
    MUSCLE & NERVE, 2022, 66 : S72 - S72
  • [30] COST OF ILLNESS, COST OF IMMUNOGLOBULIN THERAPY AND THEIR DETERMINANTS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY Reply
    Mengel, David
    Dodel, Richard
    Tackenberg, Bjoern
    MUSCLE & NERVE, 2019, 59 (03) : E23 - E23